Dexmedetomidine
In clinical developmentAlso known as Dexased, Dexdomitor, Dexmedesed, Dexmedvet+12 more
Dexased, Dexdomitor, Dexmedesed, Dexmedvet, Igalmi, Precedex, Sedexodine, Sileo, Dexmed-etomidine, Dexmedetomidin, Dexmedetomidina, Dextmedetomidine, dexemedetomidine, (+)-4-((S)-alpha,2,3-Trimethylbenzyl)imidazole, Dexmedetomidine Hydrochloride, Dexmedetomidinum.
Recent clinical, regulatory, research and industry developments relating to this drug.
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Late-stage studies
Phase III+ trials still open or recently active — where late-stage evidence is being generated.
Recent completions
Trials that read out recently, adding to the completed evidence base.
Neuroimaging Study of Dexmedetomidine-Induced Analgesia
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes8
Journals, researchers & institutions
- Paediatric anaesthesia2
- Anesthesiology1
- Clinical drug investigation1
- Hospital pediatrics1
- Intensive care medicine1
- Pain1
- Berkenbosch JW2
- Ben-Menachem E1
- Ben-Zeev B1
- Berkenstadt H1
- Borao L1
- Bourguignon N1
- Chanques G1
- Constantin JM1
- Baylor College of Medicine1
- Boston Children's Hospital1
- Centre Hospitalier d'Aurillac1
- Centre Hospitalier d'Avignon1
- Centre Hospitalier de Montluçon1
- Centre Hospitalier de Moulins Yzeure1
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials